Treatment landscape of triple-negative breast cancer—expanded options, evolving needs
Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …
Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance
S Bagchi, R Yuan, EG Engleman - Annual Review of Pathology …, 2021 - annualreviews.org
Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …
Event-free survival with pembrolizumab in early triple-negative breast cancer
Background The addition of pembrolizumab to neoadjuvant chemotherapy led to a
significantly higher percentage of patients with early triple-negative breast cancer having a …
significantly higher percentage of patients with early triple-negative breast cancer having a …
[HTML][HTML] Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer
Background In an interim analysis of this phase 3 trial, the addition of pembrolizumab to
chemotherapy resulted in longer progression-free survival than chemotherapy alone among …
chemotherapy resulted in longer progression-free survival than chemotherapy alone among …
Immune checkpoint inhibitors in cancer therapy
The discovery of immune checkpoint proteins such as PD-1/PDL-1 and CTLA-4 represents a
significant breakthrough in the field of cancer immunotherapy. Therefore, humanized …
significant breakthrough in the field of cancer immunotherapy. Therefore, humanized …
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
Immunotherapy has revolutionized cancer treatment and rejuvenated the field of tumor
immunology. Several types of immunotherapy, including adoptive cell transfer (ACT) and …
immunology. Several types of immunotherapy, including adoptive cell transfer (ACT) and …
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer …
Background Pembrolizumab monotherapy showed durable antitumour activity and
manageable safety in patients with metastatic triple-negative breast cancer. We aimed to …
manageable safety in patients with metastatic triple-negative breast cancer. We aimed to …
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆
Metastatic breast cancer (MBC) is an incurable disease, but survival improvements have
been reported with appropriate therapeutic strategies. 1-8 Systemic therapy is the standard …
been reported with appropriate therapeutic strategies. 1-8 Systemic therapy is the standard …
[HTML][HTML] A guide to cancer immunotherapy: from T cell basic science to clinical practice
AD Waldman, JM Fritz, MJ Lenardo - Nature Reviews Immunology, 2020 - nature.com
The T lymphocyte, especially its capacity for antigen-directed cytotoxicity, has become a
central focus for engaging the immune system in the fight against cancer. Basic science …
central focus for engaging the immune system in the fight against cancer. Basic science …
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
DB Doroshow, S Bhalla, MB Beasley… - Nature reviews Clinical …, 2021 - nature.com
Immune-checkpoint inhibitors targeting PD-1 or PD-L1 have already substantially improved
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …